BNP Paribas Exane analyst Peter Verdult initiated coverage of GSK (GSK) with a Neutral rating and $35.25 price target Stay Ahead of the Market: ...

GSK plc ( NYSE: GSK) has failed to meet key ethical and regulatory standards in how it marketed and provided prescribing information for its drug Omjjara, according to a ruling issued Tuesday by an ...

As we’ve been reporting, US Vice-President JD Vance says there is a “good chance” that the US and UK will come to a mutually ...